Emerging Viral and Bacterial Infections: Within an Era of Opioid Epidemic.
Bacterial infection
Hepatitis C
Opioid use disorder
Viral infection
Journal
Infectious diseases and therapy
ISSN: 2193-8229
Titre abrégé: Infect Dis Ther
Pays: New Zealand
ID NLM: 101634499
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
29
06
2020
pubmed:
13
9
2020
medline:
13
9
2020
entrez:
12
9
2020
Statut:
ppublish
Résumé
The opioid epidemic is a public health crisis that continues to impact healthcare in the United States of America (USA). While changes in opioid prescribing have curbed the medical use of opioids, the increase in nonmedical use, largely driven by injection drug use (IDU), has contributed to the escalating incidence of opioid use disorder (OUD). Furthermore, IDU is associated with high-risk injection practices that can increase the risk of acquiring viral and bacterial infections. Here in this comprehensive review, we aimed to summarize the epidemiology and management of OUD, along with the screening and antimicrobial treatment of associated infections, specifically focused on human immunodeficiency virus, hepatitis C virus, skin and soft tissue infections, endocarditis, and osteomyelitis. Medication-assisted therapy (MAT) and infection guidelines from the USA will be presented.
Identifiants
pubmed: 32918275
doi: 10.1007/s40121-020-00335-0
pii: 10.1007/s40121-020-00335-0
pmc: PMC7680496
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
737-755Références
Guy GP, Jr, Zhang K, Bohm MK, et al. Vital signs: changes in opioid prescribing in the United States, 2006–2015. MMWR Morb Mortal Wkly Rep. 2017;66(26) https://www.cdc.gov/mmwr/volumes/66/wr/mm6626a4.htm?s_cid=mm6626a4_w .
Florence CS, Zhou C, Luo F, Xu L. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Med Care. 2016;54:901–6.
pubmed: 27623005
pmcid: 5975355
Wide-ranging online data for epidemiologic research (WONDER). Atlanta, GA: CDC, National Center for Health Statistics; 2020. https://wonder.cdc.gov .
Saxon AJ. The unmet challenges of co-occurring alcohol and opioid use. Alcohol Clin Exp Res. 2018. https://doi.org/10.1111/acer.13797 .
doi: 10.1111/acer.13797
pubmed: 29846946
Kosten TR, George TP. The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect. 2002;1(1):13–20. https://doi.org/10.1151/spp021113 .
doi: 10.1151/spp021113
pubmed: 18567959
pmcid: 2851054
Hedegaard H, Miniño AM, Warner M. Drug overdose deaths in the United States, 1999–2018.pdf icon NCHS Data Brief, no 356. Hyattsville, MD: National Center for Health Statistics. 2020.
Centers for Disease Control and Prevention (CDC). Vital signs: overdoses of prescription opioid pain relievers—United States, 1999–2008. MMWR MorbMortal Wkly Rep. 2011;60(43):1487–92.
Rudd RA, Paulozzi LJ, Bauer MJ, et al. Increases in heroin overdose deaths—28 states, 2010 to 2012. MMWR MorbMortal Wkly Rep. 2014;63(39):849.
Gladden RM, Martinez P, Seth P. Fentanyl law enforcement submissions and increases in synthetic opioid-involved overdose deaths—27 states, 2013–2014. MMWR MorbMortal Wkly Rep. 2016;65:837–43.
O’Donnell JK, Gladden RM, Seth P. Trends in deaths involving heroin and synthetic opioids excluding methadone, and law enforcement drug product reports, by census region—United States, 2006–2015. MMWR MorbMortal Wkly Rep. 2017;66:897–903.
O’Donnell JK, Halpin J, Mattson CL, Goldberger BA, Gladden RM. Deaths involving fentanyl, fentanyl analogs, and U-47700—10 states, July–December 2016. MMWR Morb Mortal Wkly Rep. 2017;66:1197–202.
pubmed: 29095804
pmcid: 5689219
Vardanyan RS, Hruby VJ. Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications. Future Med Chem. 2014;6(4):385–412. https://doi.org/10.4155/fmc.13.215 .
doi: 10.4155/fmc.13.215
pubmed: 24635521
pmcid: 4137794
Drug Enforcement Administration. 2019 National Drug Threat Assessment. Drug Enforcement Administration Strategic Intelligence Section, U.S. Department of Justice. Published December 2019. https://www.dea.gov/sites/default/files/2020-01/2019-NDTA-final-01-14-2020_Low_Web-DIR-007-20_2019.pdf . Accessed March 17, 2020
SAMHSA, 2011. Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-41, HHS Publication No. (SMA) 11-4658, Rockville, MD.
Wilson N, Kariisa M, Seth P, et al. Drug and opioid-involved overdose deaths—United States, 2017–2018. MMWR Morb Mortal Wkly Rep. 2020;69:290–7.
pubmed: 32191688
Lankenau SE, Teti M, Silva K, Jackson BJ, Harocopos A, Treese M. Initiation into prescription opioid misuse amongst young injection drug users. Int J Drug Policy. 2012;23:37–44.
pubmed: 21689917
Jones CM. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers—United States, 2002–2004 and 2008–2010. Drug Alcohol Depend. 2013;132(1–2):95–100.
pubmed: 23410617
Compton WM, Jones CM, Baldwin GT. Relationship between nonmedical prescription-opioid use and heroin use. N Engl J Med. 2016;374(2):154–63. https://doi.org/10.1056/NEJMra1508490 .
doi: 10.1056/NEJMra1508490
pubmed: 26760086
Peavy KM, Banta-Green CJ, Kingston S, Hanrahan M, Merrill JO, Coffin PO. “Hooked on” prescription-type opiates prior to using heroin: results from a survey of exchange clients. J Psychoactive Drugs. 2012;44:259–65.
pubmed: 23061326
Lyden J, Binswanger IA. The United States opioid epidemic. Semin Perinatol. 2019. https://doi.org/10.1053/j.semperi.2019.01.001 .
doi: 10.1053/j.semperi.2019.01.001
pubmed: 30711195
pmcid: 6578581
Wiese AD, Griffin MR, Schaffner W, et al. Long-acting opioid use and the risk of serious infections: a retrospective cohort study. Clin Infect Dis. 2018. https://doi.org/10.1093/cid/ciy809 .
doi: 10.1093/cid/ciy809
pubmed: 29672667
pmcid: 6522680
Schranz AJ, Barrett J, Hurt CB, Malvestutto C, Miller WC. Challenges facing a rural opioid epidemic: treatment and prevention of HIV and hepatitis C. Curr HIV/AIDS Rep. 2018;15:245–54.
pubmed: 29796965
pmcid: 6085134
Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506–13. https://doi.org/10.1016/S0140-6736(11)60358-9 .
doi: 10.1016/S0140-6736(11)60358-9
pubmed: 21529928
Gibson AE, Degenhardt LJ. Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records. Drug Alcohol Rev. 2007;26(4):405–10. https://doi.org/10.1080/09595230701373834 .
doi: 10.1080/09595230701373834
pubmed: 17564876
Low AJ, Mburu G, Welton NJ, et al. Impact of opioid substitution therapy on antiretroviral therapy outcomes: a systematic review and meta-analysis. Clin Infect Dis. 2016;63(8):1094–104. https://doi.org/10.1093/cid/ciw416 .
doi: 10.1093/cid/ciw416
pubmed: 27343545
pmcid: 5036913
Des Jarlais DC, Perlis T, Arasteh K, et al. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990–2001. AIDS. 2005;19(Suppl 3):S20–S2525. https://doi.org/10.1097/01.aids.0000192066.86410.8c .
doi: 10.1097/01.aids.0000192066.86410.8c
pubmed: 16251819
Winstanley EL, Stover AN. The impact of the opioid epidemic on children and adolescents. Clin Ther. 2019;41(9):1655–62. https://doi.org/10.1016/j.clinthera.2019.06.003 .
doi: 10.1016/j.clinthera.2019.06.003
pubmed: 31303278
pmcid: 7017799
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. https://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf . Accessed March 28, 2020
HIV: Statistics overview. Atlanta, GA: Centers for Disease Control and Prevention; November 21, 2019. www.cdc.gov/hiv/statistics/overview/index.html . Accessed March 28, 2020
Kipke MD, Weiss G, Wong CF. Residential status as a risk factor for drug use and HIV risk among young men who have sex with men. AIDS Behav. 2007;11(6 Suppl):56–69. https://doi.org/10.1007/s10461-006-9204-5 .
doi: 10.1007/s10461-006-9204-5
pubmed: 17265143
pmcid: 2930767
Crooks D, Tsui J, Anderson B, et al. Differential risk factors for HIV drug and sex risk-taking among non-treatment-seeking hospitalized injection drug users. AIDS Behav. 2015;19(3):405–11. https://doi.org/10.1007/s10461-014-0754-7 .
doi: 10.1007/s10461-014-0754-7
pubmed: 25063229
pmcid: 4861062
Viral hepatitis surveillance—United States, 2015. Atalnta, GA: Centers for Disease Control and Prevention; November 2016. www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2015-vol-27.pdf . Accessed April 19, 2020.
Hepatitis C Prevalence Estimates 2013–2016. Atlanta, GA: Centers for Disease Control and Prevention; November 6, 2018. www.cdc.gov/nchhstp/newsroom/2018/hepatitis-c-prevalence-estimates.html . Accessed March 28, 2020
Hepatitis C Online. Seattle, WA; University of Washington; July 17, 2018. www.hepatitisc.uw.edu . Accessed March 28, 2020.
Schulte M, Hser Y, Saxon A, et al. Risk factors associated with HCV among opioid-dependent patients in a multisite study. J Community Health. 2015;40(5):940–7. https://doi.org/10.1007/s10900-015-0016-2 .
doi: 10.1007/s10900-015-0016-2
pubmed: 25814381
pmcid: 4558248
HCV guidance: recommendations for testing, managing, and treating hepatitis C. www.hcvguidelines.org . HVCGuidelines.org website. Accessed March 28, 2020.
Ramakrishnan K, Salinas R, Higuita N, et al. Skin and soft tissue infections. Am Fam Physician. 2015 Sep 15;92(6):474–83.
pubmed: 26371732
Stevens D, Bisno A, Chambers H, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. CID. 2014;59(2):e10–52.
Kadri A, Wilner B, Hernandez A, et al. Geographic trends, patient characteristics, and outcomes of infective endocarditis associated with drug abuse in the United States from 2002 to 2016. J Am Heart Assoc. 2019;8(19):e012969.
Baddour L, Wilson W, Bayer A, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications. A scientific statement for healthcare professionals from the American Heart Association. AHA. 2015;132:1435–86.
Wald E. Risk factors for osteomyelitis. Am J Med. 1985;78(6B):206–12.
pubmed: 3893117
Hatzenbuehler J, Pulling T. Diagnosis and management of osteomyelitis. Am Fam Physician. 2011;84(9):1027–33.
pubmed: 22046943
Berbari E, Kanj S, Kowalski T, et al. 2015 Infectiou Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. Clin Infect Dis. 2015;61(6):e26–46.
pubmed: 26229122
Schwetz TA, Calder T, Rosenthal E, Kattakuzhy S, Fauci AS. Opioids and infectious diseases: a converging public health crisis. J Infect Dis. 2019;220(3):346–9. https://doi.org/10.1093/infdis/jiz133 .
doi: 10.1093/infdis/jiz133
pubmed: 30941402
pmcid: 6941614
Zule WA, Oramasionwu C, Evon D, et al. Event-level analyses of sex-risk and injection-risk behaviors among nonmedical prescription opioid users. Am J Drug Alcohol Abuse. 2016;42(6):689–97. https://doi.org/10.1080/00952990.2016.1174706 .
doi: 10.1080/00952990.2016.1174706
pubmed: 27285847
pmcid: 5661892
HIV and people who inject drugs. Atlanta, GA: Centers for Disease Control and Prevention; February 6,2020. www.cdc.gov/hiv/group/hiv-idu.html . Accessed March 28, 2020
Hoots BE, Finlayson TJ, Broz D, Paz-Bailey G. Antiretroviral therapy use among HIV-infected people who inject drugs—20 cities, United States, 2009–2015. J Acquir Immune Defic Syndr. 1999;2017(75 Suppl 3):S392–S396396.
Griffith DC, Farmer C, Gebo KA, et al. Uptake and virological outcomes of single- versus multi-tablet antiretroviral regimens among treatment-naïve youth in the HIV Research Network. HIV Med. 2019;20(2):169–74. https://doi.org/10.1111/hiv.12695 .
doi: 10.1111/hiv.12695
pubmed: 30561888
Williams EC, Joo YS, Lipira L, Glass JE. Psychosocial stressors and alcohol use, severity, and treatment receipt across human immunodeficiency virus (HIV) status in a nationally representative sample of US residents. Subst Abus. 2017;38(3):269–77.
pubmed: 27925867
Crane HM, McCaul ME, Chander G, et al. Prevalence and factors associated with hazardous alcohol use among persons living with HIV across the US in the current era of antiretroviral treatment. AIDS Behav. 2017;21(7):1914–25.
pubmed: 28285434
pmcid: 5628735
Scott-Sheldon LAJ, Carey KB, Johnson BT, Carey MP, MASH Research Team. behavioral interventions targeting alcohol use among people living with HIV/AIDS: a systematic review and meta-analysis. AIDS Behav. 2017;21(Suppl 2):126–43. https://doi.org/10.1007/s10461-017-1886-3 .
doi: 10.1007/s10461-017-1886-3
pubmed: 28831609
pmcid: 5660648
Helleberg M, May MT, Ingle SM, et al. Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. AIDS. 2015;29(2):221–9.
pubmed: 25426809
pmcid: 4284008
Lesko CR, Tong W, Moore RD, Lau B. Retention, antiretroviral therapy use and viral suppression by history of injection drug use among HIV-infected patients in an urban HIV clinical cohort. AIDS Behav. 2017;21(4):1016–24. https://doi.org/10.1007/s10461-016-1585-5 .
doi: 10.1007/s10461-016-1585-5
pubmed: 27752872
pmcid: 5344751
Fernandes RM, Cary M, Duarte G, et al. Effectiveness of needle and syringe programmes in people who inject drugs—an overview of systematic reviews. BMC Public Health. 2017;17(1):309. https://doi.org/10.1186/s12889-017-4210-2 .
doi: 10.1186/s12889-017-4210-2
pubmed: 28399843
pmcid: 5387338
Syringe Services Programs (SSPs). Atlanta, GA: Centers for Disease Control and Prevention; May 23, 2019. https://www.cdc.gov/ssp/syringe-services-programs-faq.html
Des Jarlais DC, et al. HIV incidence among injection drug users in New York City, 1990 to 2002: use of serologic test algorithm to assess expansion of HIV prevention services. Am J Public Health. 2005;95(8):1439–44.
pubmed: 15985649
pmcid: 1449378
Des Jarlais DC, et al. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990–2001. Aids. 2005;19:S20–S2525.
pubmed: 16251819
New hepatitis C infections nearly tripled over five years [press release]. Atlanta, GA: Centers for Disease Control and Prevention; May 11, 2017. www.cdc.gov/media/releases/2017/p-hepatitis-c-infections-tripled.html . Accessed March 28, 2020.
Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review [published correction appears in Lancet Glob Health. 2017 Nov 15]. Lancet Glob Health. 2017;5(12):e1192–e1207207. https://doi.org/10.1016/S2214-109X(17)30375-3 .
doi: 10.1016/S2214-109X(17)30375-3
pubmed: 29074409
pmcid: 5683738
Salemovic D, Pesic-Pavlovic I, Jevtovic D, et al. Intravenous drug use—an independent predictor for HCV genotypes 3 and 4 infection among HIV/HCV co-infected patients. Arch Med Sci. 2017;13(3):652–8. https://doi.org/10.5114/aoms.2017.66022 .
doi: 10.5114/aoms.2017.66022
pubmed: 28507583
pmcid: 5420631
Norton BL, Fleming J, Bachhuber MA, et al. High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic. Int J Drug Policy. 2017;47:196–201. https://doi.org/10.1016/j.drugpo.2017.07.021 .
doi: 10.1016/j.drugpo.2017.07.021
pubmed: 28811158
pmcid: 5822435
Litwin AH, Agyemang L, Akiyama M, et al. The PREVAIL Study: intensive models of HCV care for people who inject drugs. J Hepatol. 2017;66:S72. https://doi.org/10.1016/S0168-8278(17)30406-3 .
doi: 10.1016/S0168-8278(17)30406-3
Jackson K, Bohm M, Brooks J, et al. Invasive methicillin-resistant Staphylococcus aureus infections among persons who inject drugs—six sites, 2005–2016. MMWR. 2018;67(22):625–8.
pubmed: 29879096
Ebright J, Pieper B. Skin and soft tissue infections in injection drug users. Infect Dis Clin North Am. 2002;16(3):697–712.
pubmed: 12371123
Dupuy A, Benchikhi H, Roujeau J, et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ. 1999;318(7198):1591–4.
pubmed: 10364117
pmcid: 28138
Ray G, Suaya J, Baxter R. Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a US population: a retrospective population-based study. BMC Infect Dis. 2013;13:252.
pubmed: 23721377
pmcid: 3679727
Binswanger I, Kral A, Bluthenthal R, et al. High prevalence of abscesses and cellulitis among community-recruited injection drug users in San Francisco. Clin Infect Dis. 2000;30(3):579–81.
pubmed: 10722447
Phillips K, Stein M. Risk practices associated with bacterial infections among injection drug users in Denver, CO. Am J Drug Alcohol Abuse. 2010;36(2):92–7.
pubmed: 20337504
pmcid: 4869685
Lavender T, McCarron B. Acute infections in intravenous drug users. Clin Med. 2013;13:511–3.
Raff AB, Kroshinsky D. Cellulitis: a review. JAMA. 2016;316(3):325–37.
pubmed: 27434444
Bernard P, Bedane C, Denis F, et al. Streptococcal cause of erysipelas and cellulitis in adults. A microbiologic study using a direct immunofluorescence technique. Arch Dermatol. 1989;125(6):779.
pubmed: 2658843
Jeng A, Beheshti M, Li J, et al. The role of beta-hemolytic streptococci in causing diffuse, nonculturable cellulitis: a prospective investigation. Medicine (Baltimore). 2010;89(4):217.
Summanen P, Talan D, Strong C, et al. Bacteriology of skin and soft-tissue infections: comparison of infections in intravenous drug users and individuals with no history of intravenous drug use. Clin Infect Dis. 1995;20(suppl 2):S279.
pubmed: 7548575
Moran G, Krishnadasan A, Gorwitz R, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355(7):666.
pubmed: 16914702
Deo S, Raza S, Kalra A, et al. Admissions for infective endocarditis in intravenous drug users. J Am Coll Cardiol. 2018;71(14):1596–7.
pubmed: 29622169
Njoroge L, Al-Kindi S, Koromia G, et al. Changes in the association of rising infective endocarditis with mortality in people who inject drugs. JAMA Cardiol. 2018;3(8):779–80.
pubmed: 29926083
pmcid: 6143071
Hartman L, Barnes E, Bachmann L, et al. Opiate injection-associated infective endocarditis in the Southeastern United States. Am J Med Sci. 2016;32(6):603–8.
Moreillon P, Que Y. Infective endocarditis. Lancet. 2004;363(9403):139.
pubmed: 14726169
Matthew J, Addai T, Anand A, et al. Clinical features, site of involvement, bacteriologic findings, and outcomes of infective endocarditis in intravenous drug users. Arch Intern Med. 1995;155(15):1641.
Bisbe J, Miro J, Moreno A, et al. Disseminated candidiasis in addict who use brown heroin: report of 83 cases and review. Clin Infect Dis. 1992;15(6):910.
pubmed: 1457662
Shekar R, Rice T, Zierdt C, et al. Outbreak of endocarditis caused by Pseudomonas aeruginosa serotype O11 among pentazocine and tripelennamine abusers in Chicago. J Infect Dis. 1985;151(2):203.
pubmed: 3918121
Ribera E, Jimenez J, Cortes E, et al. Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis. A randomized controlled trial. Ann Intern Med. 1996;125(12):969–74.
pubmed: 8967707
Cosgrove S, Vigliani G, Fowler V, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis. 2009;48:713–21.
pubmed: 19207079
Sia I, Berbari E. Osteomyelitis. Best Practice Res Clin Rheumatol. 2006;20(6):1065–81.
Yuschak E, Chase S, Haq F, et al. Demographics and length of stay for osteomyelitis in opioid drug users: a unique population with high healthcare costs. Cureus. 2019;11(3):e4339.
pubmed: 31187004
pmcid: 6541152
Seval N, Eaton E, Springer SA. Beyond antibiotics: a practical guide for the infectious disease physician to treat opioid use disorder in the setting of associated infectious diseases. Open Forum Infect Dis. 2019;7(1):ofz539.
pubmed: 31993454
pmcid: 6979000